Advertisement
Australia markets closed

  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     

  • AUD/USD

    0.6444
    -0.0007 (-0.11%)
     

  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     

  • OIL

    82.33
    +0.43 (+0.53%)
     

  • GOLD

    2,314.90
    -31.50 (-1.34%)
     

  • Bitcoin AUD

    102,869.82
    +421.10 (+0.41%)
     

  • CMC Crypto 200

    1,395.29
    -19.47 (-1.38%)
     

Was Atea Pharmaceutical's Flop Predictable?

Patrick Bafuma, The Motley Fool
·5-min read
Was Atea Pharmaceutical's Flop Predictable?

This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. Unfortunately, investors are unlikely to see the small-cap biotech replicate Moderna's success as the next COVID-19 underdog success story after news of its negative clinical trial. Let's explore what caused Atea's drop and how biotech investors should examine their future investments.

Continue reading